Rigontec, the leader in RIG-I targeting RNA therapeutics, today announced that it has secured EUR 15 million in a third and final closing of its Series A round. The financing represents additional capital from current investors Boehringer Ingelheim Venture Fund, Forbion Capital Partners, High-Tech Gründerfonds (HTGF), NRW.BANK, MP Healthcare Venture Management, Sunstone Capital and Wellington Partners Life Sciences. The funding will advance the ongoing development of Rigontec’s RIG-I agonist platform targeting oncological, anti-infective and inflammatory indications as well as accelerate the progress of lead candidate RGT100 towards the clinic.
“We are very grateful for the continued support from our investors,” said Christian Schetter, CEO of Rigontec. “This funding puts us in a great position to further expand our RIG-I targeting preclinical pipeline and propel our first program into the clinic by early 2017. It also emphasizes the unique and innovative potential our technology holds.”